๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ

๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ An ๐“ฒ๐“ท๐“ฒ๐“ฝ๐“ฒ๐“ช๐“ฝ๐“ฒ๐“ฟ๐“ฎ that encourages ๐•‹๐”ผ๐”ธ๐•„๐•Ž๐•†โ„๐•‚ towards ยซscience, education and technologyยป.

07/11/2025

MEM ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ

BICARICU-2 RCT / The outcomes.   European Society of Intensive Care Medicine (ESICM) ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ
29/10/2025

BICARICU-2 RCT / The outcomes.


European Society of Intensive Care Medicine (ESICM)
๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ

ANDROMEDA-SHOCK-2 RCT / The algorithm used    European Society of Intensive Care Medicine (ESICM) ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ
29/10/2025

ANDROMEDA-SHOCK-2 RCT / The algorithm used


European Society of Intensive Care Medicine (ESICM)
๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ

The 2nd study presented in the main session โžฉ population. / The 2nd study presented in the main session โžฉ intervention. ...
29/10/2025

The 2nd study presented in the main session โžฉ population. / The 2nd study presented in the main session โžฉ intervention.

European Society of Intensive Care Medicine (ESICM) ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ

Next SESSION โžฉ ECHO clinical interpretation.    European Society of Intensive Care Medicine (ESICM) ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ
29/10/2025

Next SESSION โžฉ ECHO clinical interpretation.


European Society of Intensive Care Medicine (ESICM)
๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ

Education โžฉ  ESICM 2025    ISICEMEuropean Society of Intensive Care Medicine (ESICM) ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ
29/10/2025

Education โžฉ ESICM 2025

ISICEM
European Society of Intensive Care Medicine (ESICM) ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ

Sepsis-associated va sepsis-induced AKI-Definition and epidemiology of SA- AkI    European Society of Intensive Care Med...
28/10/2025

Sepsis-associated va sepsis-induced AKI
-Definition and epidemiology of SA- AkI

European Society of Intensive Care Medicine (ESICM)
๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ

E-learning | ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ---------------------------------๐™ต๐™พ๐š ๐™ท๐™ด๐™ฐ๐™ป๐šƒ๐™ท๐™ฒ๐™ฐ๐š๐™ด ๐™ฟ๐š๐™พ๐š…๐™ธ๐™ณ๐™ด๐š๐š‚ / ๐™ฟ๐™ฐ๐š๐™ฐ ๐™ฟ๐š๐™พ๐š…๐™ด๐™ด๐™ณ๐™พ๐š๐™ด๐š‚ ๐™ณ๐™ด ๐š‚๐™ฐ๐™ป๐š„๐™ณ๐๐š๐ญ๐ข๐ž๐ง๐ญ-๐‚๐ž๐ง๐ญ๐ž...
13/10/2025

E-learning | ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ
---------------------------------
๐™ต๐™พ๐š ๐™ท๐™ด๐™ฐ๐™ป๐šƒ๐™ท๐™ฒ๐™ฐ๐š๐™ด ๐™ฟ๐š๐™พ๐š…๐™ธ๐™ณ๐™ด๐š๐š‚ / ๐™ฟ๐™ฐ๐š๐™ฐ ๐™ฟ๐š๐™พ๐š…๐™ด๐™ด๐™ณ๐™พ๐š๐™ด๐š‚ ๐™ณ๐™ด ๐š‚๐™ฐ๐™ป๐š„๐™ณ
๐๐š๐ญ๐ข๐ž๐ง๐ญ-๐‚๐ž๐ง๐ญ๐ž๐ซ๐ž๐ ๐€๐ฉ๐ฉ๐ซ๐จ๐š๐œ๐ก๐ž๐ฌ ๐ญ๐จ ๐๐š๐ฏ๐ข๐ ๐š๐ญ๐ข๐ง๐  ๐Œ๐ฎ๐ฅ๐ญ๐ข๐ฉ๐ฅ๐ž ๐’๐œ๐ฅ๐ž๐ซ๐จ๐ฌ๐ข๐ฌ ๐ƒ๐ข๐ฌ๐ž๐š๐ฌ๐ž ๐๐ซ๐จ๐ ๐ซ๐ž๐ฌ๐ฌ๐ข๐จ๐ง: ๐€ ๐“๐จ๐จ๐ฅ๐ค๐ข๐ญ ๐Ÿ๐จ๐ซ ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐๐ซ๐จ๐ฏ๐ข๐๐ž๐ซ๐ฌ ๐š๐ง๐ ๐“๐ก๐ž๐ข๐ซ ๐๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ
This toolkit includes practical approaches to guide providers and patients in detecting subtle signs of MS progression and offers comprehensive strategies for developing treatment plans based on current evidence and patient-centered practices.


๐Ÿšฅ ๐—ฆ๐˜๐—ฎ๐—ฟ๐˜ ๐—ฎ๐—ฐ๐˜๐—ถ๐˜ƒ๐—ถ๐˜๐˜†: https://primeinc.org/online/patient-centered-approaches-navigating-multiple-sclerosis-disease-progression
---------------------------------
โœ” ๐—˜ -๐—น๐—ฒ๐—ฎ๐—ฟ๐—ป๐—ถ๐—ป๐—ด: https://www.inaaqc.org/e-learning

๐ƒ๐š๐ฉ๐š๐ ๐ฅ๐ข๐Ÿ๐ฅ๐จ๐ณ๐ข๐ง๐š ๐ฆรก๐ฌ ๐ซ๐ž๐ฌ๐ญ๐ซ๐ข๐œ๐œ๐ขรณ๐ง ๐œ๐š๐ฅรณ๐ซ๐ข๐œ๐š ๐ฉ๐š๐ซ๐š ๐ฅ๐š ๐ซ๐ž๐ฆ๐ข๐ฌ๐ขรณ๐ง ๐๐ž ๐ฅ๐š ๐๐ข๐š๐›๐ž๐ญ๐ž๐ฌ ๐ญ๐ข๐ฉ๐จ ๐Ÿ En conclusiรณn, el rรฉgimen de dapagliflozi...
12/10/2025

๐ƒ๐š๐ฉ๐š๐ ๐ฅ๐ข๐Ÿ๐ฅ๐จ๐ณ๐ข๐ง๐š ๐ฆรก๐ฌ ๐ซ๐ž๐ฌ๐ญ๐ซ๐ข๐œ๐œ๐ขรณ๐ง ๐œ๐š๐ฅรณ๐ซ๐ข๐œ๐š ๐ฉ๐š๐ซ๐š ๐ฅ๐š ๐ซ๐ž๐ฆ๐ข๐ฌ๐ขรณ๐ง ๐๐ž ๐ฅ๐š ๐๐ข๐š๐›๐ž๐ญ๐ž๐ฌ ๐ญ๐ข๐ฉ๐จ ๐Ÿ
En conclusiรณn, el rรฉgimen de dapagliflozina mรกs restricciรณn calรณrica regular logrรณ una tasa mucho mayor de remisiรณn de la diabetes en comparaciรณn con la restricciรณn calรณrica sola en pacientes con sobrepeso u obesidad con DM 2.

( )

โ–บ ๐Ž๐ซ๐ข๐ ๐ข๐ง๐š๐ฅ ๐ฌ๐จ๐ฎ๐ซ๐œ๐ž: Liu Y, Chen Y, Ma J et al, Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial BMJ 2025;388: e081820
โ–บ ๐—ฆ๐—ฒ๐—ฐ๐—ผ๐—ป๐—ฑ๐—ฎ๐—ฟ๐˜† ๐˜€๐—ผ๐˜‚๐—ฟ๐—ฐ๐—ฒ: https://www.inaaqc.org/2025_asobat

Adres

Route De Lennik 804
Brussels

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Contact De Praktijk

Stuur een bericht naar ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ:

Delen

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram